Tag: ILMN

Illumina Supports Norway’s Pioneering Precision Medicine Study

SAN DIEGO, Dec. 9, 2021 /PRNewswire/ — Illumina, Inc. (NASDAQ:ILMN), today announced that it is supporting a national precision medicine study in Norway to assess the efficacy of blood-based comprehensive genomic profiling (CGP) in cancer therapy selection testing. The study will also evaluate the cost-effectiveness of implementing blood-based CGP in…

Continue Reading Illumina Supports Norway’s Pioneering Precision Medicine Study

Staff Bioinformatics Scientist at GRAIL

Job Description GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation…

Continue Reading Staff Bioinformatics Scientist at GRAIL

European Commission seeks to intervene in Illumina’s acquisition of Grail

In an unusual step, the European Commission plans to intervene in the recent merger between Illumina (ILMN) and Grail because regulators were unable to finish reviewing the deal before it was completed, raising concerns that competition in the market for DNA sequencing tests will now be damaged. The move comes…

Continue Reading European Commission seeks to intervene in Illumina’s acquisition of Grail

Illumina (ILMN), Grail Merger Sees Futher Regulatory Challenges

The high voltage drama surrounding the Illumina ILMN-Grail consolidation is showing no signs of drawing to a close. Following the completion of this longstanding and highly-disputed $7.1 billion merger last week without regulatory approvals, investors are currently waiting to see the magnitude of penalty that the European Commission (EC) might…

Continue Reading Illumina (ILMN), Grail Merger Sees Futher Regulatory Challenges